Table 1.
A summary of Phase I and II peptide-based cancer vaccine clinical trials currently active or recruiting.
| Condition | Peptide Vaccine Type | NCT number |
|---|---|---|
| Adenocarcinoma | HER2/neu Peptides | NCT02795988 |
| Personalised Peptide Vaccine | NCT04627246, NCT02600949 | |
| Bladder Cancer | Personalised Peptide Vaccine | NCT03359239 |
| Blood Cancer & Leukaemia | Multiple Peptides | NCT04051307 |
| Personalised Peptide Vaccine Combination Therapy | NCT04688385, NCT03559413, NCT02802943 | |
| WT1 Peptides | NCT04747002, NCT03761914 | |
| IDO Peptides | NCT03939234 | |
| Survivin Peptides | NCT02334865 | |
| Brain Cancer | TAA Peptide Combination Therapy | NCT01795313 |
| IDH1 Peptide | NCT02193347 | |
| Breast Cancer | Folate Receptor Peptide Combination Therapy | NCT02593227, NCT03012100 |
| HER2/neu Peptides | NCT02636582, NCT00194714, NCT04144023, NCT04024800, NCT04197687, NCT03384914 | |
| Novel Peptides | NCT02826434, NCT03362060 | |
| Personalised Peptide Vaccine Combination Therapy | NCT03606967, NCT02427581 | |
| ESR1 Peptide | NCT04270149 | |
| Cervical & Ovarian Cancers | HPV E6/E7 Liposomes Combination Therapy | NCT04580771 |
| WT1 Peptides | NCT02737787 | |
| Colorectal Cancer | MUC1 Peptides | NCT02134925 |
| Gastric Cancer | Multiple Peptides Combination Therapy | NCT03784040 |
| Glioblastoma | CMV Peptide targets | NCT02864368 |
| Novel Peptides | NCT04116658 | |
| Personalised Peptide Vaccine | NCT03223103 | |
| Survivin Peptides | NCT02455557 | |
| Telomerase-derived Peptides | NCT04280848 | |
| Glioma | Neoantigen Peptides | NCT04749641, NCT02358187, NCT01130077 |
| Neoantigen Combination Therapy | NCT03893903, NCT02960230 | |
| Multiple Peptides Combination Therapy | NCT02924038 | |
| Head & Neck Cancers | IDO Peptides | NCT04445064 |
| Kidney Cancer | Personalised Peptide Vaccine Combination Therapy | NCT02950766 |
| Liver Cancer | PKA Peptide Combination Therapy | NCT04248569 |
| Lung Cancer (inc. NSCLC) | MUC1 Peptides | NCT03300817, NCT01720836 |
| P10s-PADRE Peptide | NCT02264236 | |
| Telomerase-derived Peptides | NCT01789099, NCT02818426 | |
| Neoantigen Peptides | NCT04487093 | |
| Personalised Peptide Vaccine | NCT04397926 | |
| Lymphoma | Novel Peptides | NCT04669171 |
| Personalised Peptide Vaccine Combination Therapy | NCT03361852 | |
| Melanoma | BRAF/CD4 Epitopes | NCT04364230 |
| CD4+ Epitope peptides | NCT03617328 | |
| Novel Peptides | NCT02126579 | |
| NY-ESO & gp100 Peptide Combination Therapy | NCT01176474, NCT01176461 | |
| IDO & PD-L1 Peptide Combination Therapy | NCT03047928 | |
| Personalised Peptide Vaccine Combination Therapy | NCT04072900 | |
| Multiple Cancers & Solid Tumours | Arginase-1 Peptide | NCT03689192 |
| HER2/neu Peptides | NCT01376505 | |
| KRAS Peptide Combination Therapy | NCT04117087 | |
| Multiple Peptides | NCT04316689 | |
| Personalised Peptide Vaccine | NCT03715985 | |
| Personalised Peptide Vaccine Combination Therapy | NCT03633110, NCT04266730 | |
| Survivin Peptides Combination Therapy | NCT03879694 | |
| Telomerase-derived Peptides Combination Therapy | NCT03946358 | |
| Myeloma | Novel Peptide Combination Therapy | NCT02886065 |
| PD-L1 Peptides | NCT03850522 | |
| Pancreatic Cancer | Neoantigen Peptides | NCT03956056 |
| Personalised Peptide Vaccine | NCT03558945 | |
| Prostate Cancer | Bcl-xl Peptides | NCT03412786 |
| Novel Peptide-Conjugate | NCT04701021 | |
| RhoC Peptide | NCT04114825 | |
| TARP Peptide | NCT02362464 | |
| Telomerase-derived Peptides | NCT01784913 |